We have previously demonstrated that Akt was required for repetitive ischemia (RI)-induced coronary collateral growth (CCG) in healthy rats but was not activated by RI in the metabolic syndrome (JCR:LA-cp rats) where CCG was impaired. Here we hypothesized that failure of AT1R blockers to restore Akt activation is a key determinant of their inability to completely restore CCG in the metabolic syndrome. Therefore, we investigated whether adenovirusmediated delivery of constitutively active Akt (MyrAkt-Adv) in conjunction with AT1R blockade (candesartan) was able to restore RI-induced CCG in JCR:LA-cp rats. Successful myocardial MyrAkt-Adv delivery was confirmed by a >80% transduction efficiency and an ~4 fold increase in Akt expression and activation. CCG was assessed by myocardial blood flow measurements in the normal (NZ) and collateral-dependent (CZ) zones. MyrAkt-Adv alone significantly increased RI-induced CCG in JCR:LA-cp rats (~30%), but it completely restored CCG in conjunction with administration of candesartan. In contrast, dominant negative Akt (DN-Akt-Adv) reversed the beneficial effect of candesartan on CCG in JCR:LA-cp rats. We conclude that optimal restoration of coronary collateral growth in JCR:LA-cp rats requires a combination of AT1R blockade with constitutive Akt activation. These findings may carry implications for metabolic syndrome patients in need of coronary revascularization.
we have shown to be required for CCG, Akt and p38 MAPK, in WKY animals, but partially restored their activation in JCR:LA-cp animals (22). Specifically, AT1R blockade restored p38 MAPK activation to a profile observed in response to RI in WKY animals, which was associated with CCG (22). However, while AT1R blockade activated Akt at day 3 of the RI protocol to a level similar to that in WKY animals, it failed to elicit the sustained Akt activation observed to be associated with CCG in WKY animals (22). Thus, the inability of AT1R blockers to restore Akt activation to a temporal pattern shown to be associated with CCG may underlie the inability of AT1R blockers to fully restore CCG in the metabolic syndrome. Consequently, we hypothesized that restoration of Akt activation in the metabolic syndrome JCR:LA-cp rats, in combination with AT1R blockade, would restore CCG in the these animals to levels seen in response to RI in normal, healthy rats. Furthermore, although we have previously demonstrated an association between impaired RI-induced CCG in the metabolic syndrome, and lack of Akt activation, we have not established a definitive role for Akt in collateral growth in the metabolic syndrome.
Lastly, an association between prolonged and/or excessive Akt activation and impaired angiogenesis has been reported (14) ; thus, the true benefit of sustained Akt activation in CCG remains undefined.
Therefore, in the present study, we focused on establishing a clinically relevant paradigm for maximal restoration of CCG in the metabolic syndrome. Specifically, the goal of this study was to assess whether delivery of constitutively active Akt to the myocardium may induce CCG as alternative to conventional methods of coronary revascularization, with specific relevance to a sub-population of metabolic syndrome patients, those suffering from stable angina and already being treated with AT1R blockers. We determined whether in vivo delivery of constitutively active Akt (MyrAkt) alone, or in conjunction with AT1R blockade induced maximal restoration of RI-induced CCG in the rat model of the metabolic syndrome.
Furthermore, we investigated the importance of Akt signaling in the regulation of CCG by delivering dominant negative Akt (DN-Akt) to rats treated with AT1R blockers. measurements of coronary blood flow at day 0 and day 10 of RI in the same animal. Boundaries of the CZ were determined both visually at the time of initial surgery as blanching upon LAD occlusion (occluder inflation) followed by reactive hyperemia upon reperfusion (occluder deflation) and by fluorescent microspheres (15µM), which were injected into the LV at the same time and in the same manner as the first set of color microspheres (gold). Blood flow in the NZ and the CZ (ml/min/g) was calculated as described previously, according to the formula Blood flow=[radioactive count in myocardial tissue)x(blood withdrawal rate)/radioactive count in isotonic saline by direct injection into the LV cavity at the time of initial surgery (day 0 RI) during a 20 sec aortic occlusion followed by a 40 sec LAD occlusion. Body weight was measured at day 0 and day 10 of RI, and heart weight (total, LV and RV) at day 10 of RI (post-sacrifice) in every animal.
In n=3 animals per group in groups treated with either DN-Akt-Adv or MyrAkt-Adv, blood flow was measured at day 10 of RI before and after intravenous administration of adenosine (5x10 5 M). Because adenosine did not alter blood flow, these animals were combined with the remaining n=3 animals, which were not treated with adenosine, for statistical analysis.
Echocardiography. All measurements were performed under sevofluorene (1-2%) anesthesia with continuous monitoring of body temperature, blood pressure and heart rate. Left ventricular end-diastolic diameter (LVEDD) and end-systolic diameter (LVESD), septal wall diastolic thickness (IVSWT) and left ventricular free (posterior) wall diastolic thickness (LVWT)
were measured by 2D guided M-mode echocardiography from the parasternal long-axis view by using a 12-38 MHz vascular probe (Vevo 770, 1,000 fps, Visual Sonics, Toronto, Ontario, Canada). Left ventricular end diastolic and systolic volumes (LVEDV and LVESV) and ejection fraction (EF) were calculated using Vevo software (Visual Sonics). All measurements were n=3
animals per group at day 0 and 10 of RI, and were analyzed by two-way ANOVA followed by Bonferroni correction. p<0.05 determined statistical significance.
Western blot analysis. Hearts were excised at day 0, 3 or 10 of RI, the CZ separated from the NZ, snap-frozen and homogenized in lysis buffer containing 0.1% SDS and 1% Triton 
Myocardial oxidative stress measurements (O 2˙-)
. O 2˙-production was evaluated using X-band electroparamagnetic resonance (EPR) in a Bruker EMX spectrometer using 1-hydroxy-3-carboxy-pyrrolidine (CP-H, Alexis, Cornerstone, CT) as a spin-trap, as previously described (22). Briefly, animals underwent 2 consecutive periods of ischemia/reperfusion, were sacrificed, candesartan lowered blood pressure (afterload), as expected, it did not have a significant effect on LV hypertrophy (Table 1) . Neither DN-Akt-Adv nor MyrAkt-Adv significantly altered cardiac structure or function, as indicated by measurements of heart weight, LV/RV weight ratio, LV weight, wall thickness, end-diastolic and end-systolic diameter and ejection fraction of treated compared to non-treated animals ( Table 1) . increase in collateral-dependent blood flow in JCR:LA-cp rats (at day 10 of RI CZ/NZ flow ratio was 0.38±0.03), but had no effect on collateral-dependent blood flow in the WKY animals (at day 10 of RI CZ/NZ flow ratio was 0.82±0.03) (Figure 1 ). EGFP-Adv was used to control for non-specific effects of Adv delivery. There was no significant difference in the CZ/NZ flow ratio between EGFP-Adv-treated animals ( Figure 1 ) and non-treated animals (either WKY or JCR for all groups) (22) indicating that EGFP-Adv administration alone had no effect on CCG.
Adenovirus
Consistent with our previous findings (13, 22) , although basal coronary flows tended to be slightly lower in the JCR animals, the difference was not statistically significant. In other words, neither NZ nor CZ flows at day 0 of RI were significantly different between WKY and JCR:LA-cp animals. Furthermore, NZ flows at day 10 of RI were not significantly different between WKY and JCR:LA-cp animals in any treatment group, nor was there any difference in NZ flows within the individual rat strains regardless of treatment (data not shown). Transduction efficiency was evaluated by administering EGFP-Adv, which has an identical viral backbone as MyrAkt-Adv. Cell-specific markers, β-MHC, the expression of which is confined specifically to cardiac myocytes, SM-α-actin, the expression of which is confined specifically to vascular smooth muscle cells (VSMC) or, Tie-2, the expression of which is confined specifically to endothelial cells (ECs), were used to determine % of EGFP-transduced cardiac myocytes, VSMCs and ECs. Transduction efficiencies were as follows: myocytes (83±4% in the CZ, 66±2% in the NZ), VSMC (82±3% in the CZ, 61±4% in the NZ), and EC (3±1% in the CZ, 4±2% in the NZ) (data not shown). High Adv-mediated transduction efficiency of cardiac myocytes and vascular cells in the CZ with the exception of ECs was confirmed by immunofluorescence using anti-β-MHC, anti-SM-α-actin or anti-Tie-2 antibodies (Figure 6 ). No adverse effects, such as cardiomyopathy or heart failure, which can be associated with longterm Adv delivery, were observed. There were no significant changes in heart weight, LV/RV weight ratio, LV weight, wall thickness, end-diastolic or end-systolic diameter, or ejection fraction compared to non-Adv-treated animals (Table 1) . Similarly, the Advs had no effect on mortality (4% for JCR:LA-cp and 0% for WKY rats which survived the initial surgery). (Table 1) .
Adenovirus-mediated delivery of constitutively active

Adenovirus-mediated delivery of dominant negative Akt (DN-
We have previously shown that vascular reactivity does not affect measurements of CCG in the coronary vasculature in either the WKY or the JCR:LA-cp rats (21). However, since
Akt is a known regulator of eNOS activation, to exclude possible confounding effects of vascular reactivity on assessment of CCG in this study, an n=3 animals from each MyrAkt-Adv-and DNAkt-Adv-treated group were treated with a vasodilator adenosine (5x10 5 M) prior to blood flow measurements at day 10 of the RI protocol. There was no difference in blood flow between these animals and the animals that did not receive adenosine (data not shown).
Basal AT1R levels are elevated in JCR:LA-cp rats. Since this study utilized AT1R
blockers, we assessed basal as well as RI-induced AT1R levels in an effort to explain the effect of candesartan on CCG. Baseline AT1R levels were elevated in the JCR:LA-cp animals (~3 fold), but were not altered by RI in either rat strain for the duration of the RI protocol (Figure 4 ).
Finally, since we have previously shown that candesartan lowered oxidative stress in both rat strains (22), we examined the effects of MyrAkt-Adv-and DN-Akt-Adv on myocardial 0 2 .-. MyrAkt-Adv elicited a small decrease and DN-Akt-Adv a small increase in myocardial 0 2 .-in both the CZ and the NZ, but these effects were not statistically significant ( Figure 5 ). EGFP-Adv had no effect on myocardial 0 2 .-(data not shown) (22).
Discussion
The most important and clinically relevant finding in our study is that sustained Akt The controversy surrounding Akt and its effects on vascular growth might relate to the magnitude and duration of its activation; however, the mechanisms responsible for these differential effects are unclear. Prolonged Akt activation could negatively regulate insulin signaling through insulin response subtrate-1 (IRS-1) (20, 32), which has been shown to mediate protein synthesis including VEGF synthesis (36). The implications of these findings on Akt-dependent regulation of CCG in the metabolic syndrome however are difficult to predict since the metabolic syndrome is characterized by impaired insulin signaling and may not be affected by IRS-1 downregulation. On the other hand, the magnitude of Akt activation may also modulate its effect on vascular growth. Akt is known to increase NO production, and NO has been shown to decrease cell proliferation in favor of promoting cell differentiation (3). Thus, one explanation for the negative effects of Akt activation on collateral growth may be that excessive Akt activation in the early phase of collateral formation when VSMC de-differentiate (30) in order to proliferate and migrate, is detrimental to CCG. Since the level of Akt activation achieved by the MyrAkt-Adv construct in our study was similar to that achieved by RI alone and compatible with CCG in the normal, healthy animal model (Figure 2 ), we believe that excessive Akt activation was not a factor. In addition, we in this study constitutively active Akt was highly expressed for ~7 days thus remaining within the 2-week window associated with beneficial effects of Akt activation on angiogenesis. On the other hand, MyrAkt-Adv had no significant effect on basal coronary flow. We hypothesize that this is also due to the duration of MyrAkt expression in our study, which alone, without RI as a stimulus for coronary collateralization, was not sufficient to elicit increased coronary blood flow. Likewise, MyrAkt-Adv did not induce cardiac hypertrophy, likely because this process occurs over a longer period of time.
Another consideration relevant to our findings is the location of MyrAkt and DN-Akt expression, which impacts Akt activation. Based on EGFP expression, our adenoviral constructs efficiently infected cardiac myocytes and vascular smooth muscle but not the endothelium ( Figure 6 ). Since myocytes comprise 80% of cells in the whole heart by volume, the observed Akt expression and activation reflect changes primarily in myocytes with some contribution from fibroblasts and VSMCs. This could be related to the potential role of Akt in secretion of growth factors and matrix-degrading enzymes from myocytes, and to a smaller extent VSMC survival, proliferation, migration and de(differentiation). These processes are critical for CCG, and while they have not been shown to be regulated by Akt in collateral growth, they are known to be observations are also in agreement with earlier studies in which the ACE inhibitor, captopril, and the AT1R antagonist, ibesartan, reduced the incidence of myocardial lesions in the JCR:LA-cp rats without significant effect on insulin and glucose metabolism or lipid levels (26, 28, 38), as well as a study demonstrating that AT1R blockade reduced oxidative stress and increased Akt activation in the aorta and VSMC from SHR rats (11). Our study did not identify the reason why AT1R blockade failed to elicit sustained Akt activation despite reducing oxidative stress.
However, we did not measure oxidative stress throughout the RI protocol. Thus, it is possible that altered temporal regulation of oxidative stress by AT1R blockers is partially responsible.
In combination with our previous findings, these results suggest that sustained Akt activation is one of the redox-sensitive mediators required for CCG, and that its activation syndrome animals is normal. This is frequently not the case in patients that require coronary revascularization. Thus, these studies would have to be conducted in larger animal models of coronary collateral growth, the metabolic syndrome and heart failure. Finally, gender differences may have profound effect on the role Akt plays in the regulation of CCG and would have to be examined.
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